NEW YORK (GenomeWeb) – Epic Sciences said today that it has completed a $40 million Series D financing.
Hermed Capital led the round, which also included Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital, and VI Ventures.